 CHARLESTON, S.C., March 10, 2021 PRNewswire -- GlycoPath Inc., the developer of advanced bioanalytical assays based on its proprietary GlycoTyperTM immunoaffinity technology, announced the closing of its seed investment round with Bruker Corporation Nasdaq: BRKR as a new minority investor. 